Mammalian defensins: structures and mechanism of antibiotic activity

Antibiotic peptides are important effector molecules in host‐parasite interactions throughout the living world. In vertebrates, they function in first‐line host defense by antagonizing a wide range of microbes including bacteria, fungi, and enveloped viruses. The antibiotic activity is thought to be based on their cationic, amphipathic nature, which enables the peptides to impair vital membrane functions. Molecular details for such activities have been elaborated with model membranes; however, there is increasing evidence that these models may not reflect the complex processes involved in the killing of microbes. For example, the overall killing activity of the bacterial peptide antibiotic nisin is composed of independent activities such as the formation of target‐mediated pores, inhibition of cell‐wall biosynthesis, formation of nontargeted pores, and induction of autolysis. We studied the molecular modes of action of human defense peptides and tried to determine whether they impair membrane functions primarily and whether additional antibiotic activities may be found. We compared killing kinetics, solute efflux kinetics, membrane‐depolarization assays, and macromolecular biosynthesis assays and used several strains of Gram‐positive cocci as test strains. We found that membrane depolarization contributes to rapid killing of a significant fraction of target cells within a bacterial culture. However, substantial subpopulations appear to survive the primary effects on the membrane. Depending on individual strains and species and peptide concentrations, such subpopulations may resume growth or be killed through additional activities of the peptides. Such activities can include the activation of cell‐wall lytic enzymes, which appears of particular importance for killing of staphylococcal strains.

[1]  B. Neumeister,et al.  Staphylococcus aureus strains lacking D-alanine modifications of teichoic acids are highly susceptible to human neutrophil killing and are virulence attenuated in mice. , 2002, The Journal of infectious diseases.

[2]  Robert E W Hancock,et al.  Role of membranes in the activities of antimicrobial cationic peptides. , 2002, FEMS microbiology letters.

[3]  J. Travers,et al.  Cytokine Milieu of Atopic Dermatitis, as Compared to Psoriasis, Skin Prevents Induction of Innate Immune Response Genes 1 , 2003, The Journal of Immunology.

[4]  T. Ganz,et al.  Inhibition of neutrophil elastase prevents cathelicidin activation and impairs clearance of bacteria from wounds. , 2001, Blood.

[5]  R. Hancock,et al.  Mammalian host defense peptides , 2004 .

[6]  N. Fujii,et al.  An antimicrobial peptide, magainin 2, induced rapid flip-flop of phospholipids coupled with pore formation and peptide translocation. , 1996, Biochemistry.

[7]  Oscar P. Kuipers,et al.  Specific Binding of Nisin to the Peptidoglycan Precursor Lipid II Combines Pore Formation and Inhibition of Cell Wall Biosynthesis for Potent Antibiotic Activity* , 2001, The Journal of Biological Chemistry.

[8]  D. Hoover,et al.  Multiple roles of antimicrobial defensins, cathelicidins, and eosinophil-derived neurotoxin in host defense. , 2004, Annual review of immunology.

[9]  Y. Shai,et al.  Mode of action of membrane active antimicrobial peptides. , 2002, Biopolymers.

[10]  R. Hancock,et al.  The role of cationic antimicrobial peptides in innate host defences. , 2000, Trends in microbiology.

[11]  H. G. Boman,et al.  Gene‐Encoded Peptide Antibiotics and the Concept of Innate Immunity: An Update Review , 1998, Scandinavian journal of immunology.

[12]  M. Zasloff Antimicrobial peptides of multicellular organisms , 2002, Nature.

[13]  R. Epand,et al.  Relationship of membrane curvature to the formation of pores by magainin 2. , 1998, Biochemistry.

[14]  H. Sticht,et al.  Structure determination of human and murine β‐defensins reveals structural conservation in the absence of significant sequence similarity , 2001, Protein science : a publication of the Protein Society.

[15]  H. Sahl,et al.  The lantibiotic mersacidin inhibits peptidoglycan biosynthesis at the level of transglycosylation. , 1997, European journal of biochemistry.

[16]  H. Sahl,et al.  Autolytic system of Staphylococcus simulans 22: influence of cationic peptides on activity of N-acetylmuramoyl-L-alanine amidase , 1987, Journal of bacteriology.

[17]  R I Lehrer,et al.  Antimicrobial peptides of vertebrates. , 1998, Current opinion in immunology.

[18]  R. Hancock,et al.  Sublethal Concentrations of Pleurocidin-Derived Antimicrobial Peptides Inhibit Macromolecular Synthesis in Escherichia coli , 2002, Antimicrobial Agents and Chemotherapy.

[19]  D. Hoover,et al.  The structure of human beta-defensin-1: new insights into structural properties of beta-defensins. , 2001, The Journal of biological chemistry.

[20]  M. Boniotto,et al.  Effects of Positively Selected Sequence Variations in Human and Macaca fascicularis β-Defensins 2 on Antimicrobial Activity , 2004, Antimicrobial Agents and Chemotherapy.

[21]  Alessandro Tossi,et al.  Amphipathic, α‐helical antimicrobial peptides , 2000 .

[22]  S. Yonehara,et al.  Translocation of Analogues of the Antimicrobial Peptides Magainin and Buforin across Human Cell Membranes* , 2003, The Journal of Biological Chemistry.

[23]  J. Schröder,et al.  Isolation and Characterization of Human β-Defensin-3, a Novel Human Inducible Peptide Antibiotic* , 2001, The Journal of Biological Chemistry.

[24]  F C Kafatos,et al.  Phylogenetic perspectives in innate immunity. , 1999, Science.

[25]  H. Sahl,et al.  Mode of action of the peptide antibiotic nisin and influence on the membrane potential of whole cells and on cytoplasmic and artificial membrane vesicles , 1985, Antimicrobial Agents and Chemotherapy.

[26]  C. B. Park,et al.  Mechanism of action of the antimicrobial peptide buforin II: buforin II kills microorganisms by penetrating the cell membrane and inhibiting cellular functions. , 1998, Biochemical and biophysical research communications.

[27]  A. Tossi,et al.  Design of synthetic antimicrobial peptides based on sequence analogy and amphipathicity. , 1997, European journal of biochemistry.

[28]  B. Christensson,et al.  Downregulation of bactericidal peptides in enteric infections: A novel immune escape mechanism with bacterial DNA as a potential regulator , 2001, Nature Medicine.

[29]  A. Amoroso,et al.  A study of host defence peptide β-defensin 3 in primates , 2003 .

[30]  Andreas Peschel,et al.  How do bacteria resist human antimicrobial peptides? , 2002, Trends in microbiology.

[31]  William C. Parks,et al.  Secretion of microbicidal α-defensins by intestinal Paneth cells in response to bacteria , 2000, Nature Immunology.

[32]  D. Andreu,et al.  Animal antimicrobial peptides: an overview. , 1998, Biopolymers.

[33]  Robert Blumenthal,et al.  The Structure of Human β-Defensin-2 Shows Evidence of Higher Order Oligomerization* , 2000, The Journal of Biological Chemistry.

[34]  Alessandro Tossi,et al.  Amphipathic α helical antimicrobial peptides. , 2001 .

[35]  H. G. Boman Innate immunity and the normal microflora , 2000, Immunological reviews.

[36]  I. Ginsburg Cationic peptides from leukocytes might kill bacteria by activating their autolytic enzymes causing bacteriolysis: why are publications proposing this concept never acknowledged? , 2001, Blood.

[37]  Y. Shai,et al.  Mode of action of linear amphipathic α-helical antimicrobial peptides , 1998 .

[38]  O. Kuipers,et al.  Use of the cell wall precursor lipid II by a pore-forming peptide antibiotic. , 1999, Science.

[39]  A. Tossi,et al.  Molecular diversity in gene-encoded, cationic antimicrobial polypeptides. , 2002, Current pharmaceutical design.

[40]  Huey W. Huang,et al.  Action of antimicrobial peptides: two-state model. , 2000, Biochemistry.

[41]  Y. Shai,et al.  In vitro activity and mode of action of diastereomeric antimicrobial peptides against bacterial clinical isolates. , 2004, The Journal of antimicrobial chemotherapy.

[42]  A. Pardi,et al.  Solution structure of bovine neutrophil beta-defensin-12: the peptide fold of the beta-defensins is identical to that of the classical defensins. , 1995, Biochemistry.

[43]  Oleg Chertov,et al.  The Structure of Human β-Defensin-1 , 2001, The Journal of Biological Chemistry.

[44]  L. Kwak,et al.  Mammalian defensins in immunity: more than just microbicidal. , 2002, Trends in immunology.

[45]  H. Sahl,et al.  Lantibiotics: biosynthesis and biological activities of uniquely modified peptides from gram-positive bacteria. , 1998, Annual review of microbiology.

[46]  Takaaki Ohtake,et al.  Innate antimicrobial peptide protects the skin from invasive bacterial infection , 2001, Nature.

[47]  B. Neumeister,et al.  MprF-Mediated Lysinylation of Phospholipids in Staphylococcus aureus Leads to Protection against Oxygen-Independent Neutrophil Killing , 2003, Infection and Immunity.

[48]  H. Vogel,et al.  The Solution Structures of the Human β-Defensins Lead to a Better Understanding of the Potent Bactericidal Activity of HBD3 against Staphylococcus aureus * , 2002, The Journal of Biological Chemistry.

[49]  Ji Ming Wang,et al.  β-Defensins: Linking Innate and Adaptive Immunity Through Dendritic and T Cell CCR6 , 1999 .

[50]  Michael Otto,et al.  Staphylococcus aureus Resistance to Human Defensins and Evasion of Neutrophil Killing via the Novel Virulence Factor Mprf Is Based on Modification of Membrane Lipids with l-Lysine , 2001, The Journal of experimental medicine.

[51]  H. Sahl,et al.  Role of lipid‐bound peptidoglycan precursors in the formation of pores by nisin, epidermin and other lantibiotics , 1998, Molecular microbiology.

[52]  A. Driessen,et al.  University of Groningen MECHANISTIC STUDIES OF LANTIBIOTIC-INDUCED PERMEABILIZATION OF PHOSPHOLIPID-VESICLES , 2017 .

[53]  Göran Carlsson,et al.  Deficiency of antibacterial peptides in patients with morbus Kostmann: an observation study , 2002, The Lancet.

[54]  Tomas Ganz,et al.  Endogenous antimicrobial peptides and skin infections in atopic dermatitis. , 2002, The New England journal of medicine.